Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-125b
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
EVA1A
Cancer name
Hepatocellular Carcinoma
Cancer site
Liver
Treatment type
Chemotherapy
Drug
Oxaliplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
76
Male patients
48
Female patients
28
Age range and number
23(<=45)+53(>45)
PMID
Description
Analysis of oxaliplatin-sensitive and oxaliplatin-resistant HCC cell lines showed that miR-125b is downregulated in resistant cells and its overexpression in sensitive cells decreased resistance to oxaliplatin by inhibiting cell proliferation, migration and epithelialāmesenchymal transition (EMT).
Tissue resource
oxaliplatin-resistant and nonresistant hepatocellular carcinoma tissues
human hepatocellular carcinoma cell lines HepG2
human hepatocellular carcinoma cell lines Huh6
human hepatocellular carcinoma cell lines Mahlavu
human hepatocellular carcinoma cell lines SK-Hep1
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Shanghai Tenth People's Hospital
Shanghai Institute of Cell Biology
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.